Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07046156

Treatment of Overactive Bladder With Anticholinergic Agents

Sponsor: Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

View on ClinicalTrials.gov

Summary

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

Official title: Evaluation of Anticholinergic Treatment Response and Predictive Factors in Pediatric Overactive Bladder

Key Details

Gender

All

Age Range

5 Years - 17 Years

Study Type

OBSERVATIONAL

Enrollment

120

Start Date

2022-09-01

Completion Date

2026-06-01

Last Updated

2025-07-01

Healthy Volunteers

No

Interventions

DRUG

Oxybutynin Cl

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

DRUG

propiverine

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

DRUG

Tolterodine

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Locations (1)

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital

Istanbul, Turkey (Türkiye)